A blockbuster gene-editing tool has been linked to cancer — here"s how worried you should be

Shares of NantHealth Inc. soared 56% in premarket tradin.....»»

Beam Therapeutics Inc. set terms for its planned initial public offering on Monday, saying in a regulatory filing that it plans to offer 6.25 million shares priced at $15 to $17 each. The developer of gene editing technology would raise $106......»»

Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer drug Imbruvica fell short of expectations......»»

Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer drug Imbruvica fell short of expectations......»»

Shares of thinly-traded gene therapy company Genprex Inc (NASDAQ: GNPX) are soaring on more than 50 times their average volume Tuesday. 0 read more.....»»

Clarkson University Researchers at Clarkson University are working with the US Air Force to remove a group of "forever chemicals" from water. The chemicals, known as PFAS, have been associated wit.....»»

The saga over who owns the valuable patents that cover CRISPR/Cas9 gene editing took a new turn this week with a court decision that goes against the Broad Institute of Harvard and MIT and two local startups......»»

Northwestern University/Handout via REUTERS Google Health and DeepMind claim to have created an AI tool capable of .....»»

The Chinese scientist who created the world’s first “gene-edited” babies was sentenced to three years in prison in China on Monday, according to Reuters. 0 read more.....»»

Image Point Fr/Shutterstock Cancer is the second most common cause of death in the United States, after heart disease. Why any one person gets c.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Swiss drugmaker Novartis's new $90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of treatments, including Kymriah for cancer and Zolgensma for spinal muscular atrophy, in 2020......»»

Zacks.....»»

Blackstone Group Inc said on Monday it will invest $400 million in a joint venture with Swiss drug company Ferring that is working on an experimental gene therapy for bladder cancer, the private equity giant's largest ever bet on drug development......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

iStock Anal cancer is on.....»»

Crispr Therapeutics AG (NASDAQ: CRSP) shares are ripping higher after the company focused on developing gene therapies using its proprietary CRISPR/Cas9 platform said CTX001, a gene-editing therapy it's 0.....»»

Cambridge startup CRISPR Therapeutics and partner Vertex Pharmaceuticals reached what executives called a significant step this week, releasing promising early data on a drug designed to alter a person's DNA and potentially cure them of a disease......»»

Here's a r.....»»

Elaine Thompson/AP All cancers are a result of damage or genetic mutations in our DNA. But the many reasons individual cancer cases pop up in people are complex: Some are genetic and passed down from one generation to the next, and others are a result o.....»»